Oncology Video

Conference Update: ASCO and WCGIC 2023

An expert perspective on the latest data in precision oncology

Prof. Andrea Sartore-Bianchi

Publication Date

Jul 2023

I agree that this programme:

Was valuable to me

1/3

Has improved my knowledge of this topic:

2/3

Is likely to change my clinical practice:

3/3

In this clinical update video, Prof. Andrea Sartore-Bianchi shares his perspective on key data from ASCO and the World Conference on Gastrointestinal Cancer (WCGIC), 2023.

He reviews data from:

DESTINY-PanTumor02 trial in HER2-expressing solid tumours
KontRASt-01 trial in non-small cell lung cancer (NSCLC)
ADVL 1823 trial in infantile fibrosarcoma
A retrospective study on molecular profiling on advanced biliary tract cancers

Clinical Takeaways

DESTINY-PanTumour02: Study shows T-DXd to be a potential new treatment option for patients with HER2-expressing solid tumours, with higher efficacy in IHC 3+ and efficacy also in anti-HER2 pre-treated patients
KontRASt-01: JDQ443 exhibits potent antitumour activity in NSCLC with good disease control and partial responses, as well as a good tolerability profile
ADVL1823: First data in first-line treatment with larotrectinib in the NTRK+ infantile fibrosarcoma population, with data suggesting that local control (surgery) remains important to achieve long-term results
Molecular Profiling in Biliary Cancers (BTC): the study highlights the importance of conducting NGS upfront for BTC. Treatment with a matched targeted therapeutic provides benefit in terms of DCR, PFS and OS

Selected abstracts

ASCO 2023

Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing solid tumors: DESTINY-PanTumor02 (DP-02) interim results.

Abstract: LBA3000
Presenter: Funda Meric-Bernstam, MD

KontRASt-01 update: Safety and efficacy of JDQ443 in KRAS G12C-mutated solid tumors including non-small cell lung cancer (NSCLC).

Abstract: 9007
Presenter: Philippe Alexandre Cassier MD, PhD

Phase 2 study of larotrectinib in children with newly diagnosed infantile fibrosarcoma (IFS): Children’s Oncology Group (COG) ADVL1823 cohort A.

Abstract: 10008
Presenter: Theodore Willis Laetsch, MD

WCGIC 2023

SO-4 Impact of molecular profiling on survival in patients with advanced biliary tract cancers.

Short Oral Presentation Clinical Biliary Tract Cancer, Biomarkers and Translational Research
Presenter: Leony Anton

Dr Andrea Sartore-Bianchi is head of Clinical Molecular Oncology at the Department of Hematology & Oncology, Niguarda Cancer Center, Milano, Italy. He completed his medical degree at the University of Pavia in 1999, and undertook specialist training at IRCCS Policlinico San Matteo. After completing his doctoral studies, he conducted preclinical research at the Division of Clinical Pharmacology and Experimental Cancer Therapeutics in the Department of Medicine at Brown University, Rhode Island, USA. Dr Sartore-Bianchi’s main clinical and research interests include the treatment of gastrointestinal cancers, particularly colorectal carcinomas, focusing on biomarkers of sensitivity/resistance to molecular-targeted therapies and on the epidermal growth factor receptor signal transduction pathway. He is principal and co-investigator in Phase I-II-III clinical trials for gastrointestinal malignancies, and first author of research articles in the Journal of Clinical Oncology, Cancer Research, Clinical Cancer Research and PLoS One. Currently, he is adjunct Professor for the School of Specialization in Oncology and Pharmacology at the University of Milano. He has been listed among the top 30 authors of primary research papers on cancer.

Prof. Andrea Sartore-Bianchi has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Amgen, Bayer, Sanofi and Servier Pharmaceuticals.